MorphoSys Appoints New Head of Preclinical Development

MorphoSys Further Strengthens its Proprietary Development Team

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today the appointment of a new Head of Pre-clinical Development &
Project Management. Dr. Ulrich Moebius joins MorphoSys from Medigene
AG, a TecDAX listed German biopharmaceutical company. For the last
nine years, he held the position of Head of Pre-clinical Development,
where he was responsible for the company's preclinical activities in
a range of development projects predominantly in cancer and
contributed to the market approval of two medical therapies. Prior
to his tenure at Medigene, he spent five years with the Deutsches
Krebsforschungszentrum DKFZ, Heidelberg, the leading German
biomedical research institute dedicated to cancer research and two
years at the Dana-Farber Cancer Institute located in Boston,
Massachusetts, USA. Dr. Moebius has a PhD in immunology from Johannes
Gutenberg University Mainz and qualified as a professor in Immunology
at the University of Heidelberg.

"I am delighted to welcome Ulrich Moebius to the growing development
team of MorphoSys. He combines broad academic research experience in
multiple disciplines and indications with an extensive drug
development expertise in a biopharmaceutical company, which will
support us in our plans to expand our proprietary drug pipeline,"
commented Dr. Arndt Schottelius, Chief Development Officer of
MorphoSys AG."

MorphoSys's expanding proprietary product development activities are
funded by cash-flows from its partnered discovery business,
particularly the wide-ranging strategic alliance entered into with
Novartis in December 2007. MorphoSys recently announced plans to
significantly broaden its proprietary therapeutic antibody pipeline
in 2009 and the years ahead. At the end of 2009, the company expects
a total of up to eight proprietary antibody programs ongoing, with
its lead development program MOR103 in a phase 2 clinical trial and
seven programs in preclinical development and discovery stage. As
Head of Preclinical Development & Project Management Dr. Moebius will
contribute to the entire development process of MorphoSys's
proprietary antibody programs.

"I'm looking forward to working with the entire R&D team of MorphoSys
to expand the Company's proprietary pipeline and move new programs
from research and discovery stage through pre-clinical development
and into clinical trials quickly and efficiently," commented Dr.
Moebius.

For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Senior
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com

About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG

This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.